Hemostasis and Tissue Sealing Agents Market: Minimally Invasive Surgeries, Faster Recovery & Market Forecast

According to IMARC Group's latest research publication, the global hemostasis and tissue sealing agents market reached USD 7.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 12.6 Billion by 2034, exhibiting a growth rate of 5.65% during 2026-2034.

How AI is Reshaping the Future of Hemostasis and Tissue Sealing Agents Market

• Real-Time Surgical Guidance Systems Computer vision technology integrated with AI is enabling automated detection of bleeding sites and assessment of hemostatic agent effectiveness during procedures.
• Laboratory Diagnostics Optimization AI and machine learning are transforming coagulation testing and hemostasis monitoring in clinical laboratories.
• Supply Chain and Inventory Intelligence AI-driven demand forecasting systems are helping hospitals and surgical centers optimize their hemostatic agent inventories based on surgical schedules, historical usage patterns, and seasonal variations.

Access Advanced 2026 Industry Analysis & Insights

Hemostasis and Tissue Sealing Agents Industry Overview

The hemostasis and tissue sealing agents sector is experiencing robust transformation driven by surgical volume growth and aging demographics worldwide. Over 300 million surgical procedures are performed annually across global healthcare systems, with cardiovascular, orthopedic, and general surgeries representing major application areas. North America dominates with advanced healthcare infrastructure and high adoption rates of innovative products, while Asia Pacific shows the fastest expansion due to improving medical facilities and rising healthcare spending.

Hemostasis and Tissue Sealing Agents Market Trends & Drivers

The explosive growth in minimally invasive surgical techniques is reshaping demand for specialized hemostatic solutions across medical specialties. Laparoscopic and robotic-assisted procedures now represent over 60% of elective surgeries in developed markets, requiring agents that can be precisely applied through small incisions and work effectively in confined spaces.

Rising prevalence of chronic diseases requiring surgical intervention is creating sustained demand across cardiovascular, cancer, and metabolic disease treatments. The Centers for Disease Control and Prevention estimates that 48% of Americans live with chronic conditions, many requiring procedures where effective bleeding control is critical.

Technological breakthroughs in biomaterial science are expanding product capabilities and clinical applications throughout the healthcare ecosystem. Manufacturers are introducing biodegradable formulations that eliminate the need for removal procedures, with materials designed to be absorbed naturally as wounds heal.

Leading Companies Operating in the Global Hemostasis and Tissue Sealing Agents Industry

• Advanced Medical Solutions Group plc
• Artivion, Inc
• B. Braun SE
• Baxter International Inc.
• Becton, Dickinson and Company
• BioCer Entwicklungs-GmbH
• Ethicon, Inc. (Johnson & Johnson)
• Medtronic
• Pfizer Inc.
• Terumo Aortic

Hemostasis and Tissue Sealing Agents Market Report Segmentation

By Product Type:

• Topical Hemostats
• Adhesive and Tissue Sealant

Topical hemostats represent the largest segment, offering efficiency in controlling bleeding, simplicity in application, and quick action across various surgical procedures.

By Material Type:

• Collagen-based
• Oxidized Regenerated Cellulose (ORC) based
• Gelatin-based
• Polysaccharide-based
• Others

By Application:

• General Surgery
• Minimally Invasive Surgery
• Others

General surgery holds the largest market share, encompassing procedures such as appendectomies, hernia repairs, gallbladder removals, and bowel surgeries where hemostatic agents play crucial roles.

By End User:

• Hospitals
• Ambulatory Surgical Centers
• Home Care Settings
• Others

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America dominates the hemostasis and tissue sealing agents market due to highly developed healthcare infrastructure with access to advanced medical technologies and skilled healthcare professionals.

Recent News and Developments in Hemostasis and Tissue Sealing Agents Market

• January 2026: Teleflex received FDA clearance for a next-generation fibrin sealant matrix, reducing operation times by up to 20% in orthopedic surgeries and demonstrating significant improvements in surgical efficiency.
• December 2025: Baxter International launched an advanced thrombin-based hemostatic agent with improved clotting speed for trauma surgeries, gaining rapid FDA clearance. The company also introduced an advanced collagen-based hemostatic matrix with improved biocompatibility targeting trauma care in emergency settings.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.